Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 3
1978 1
1981 4
1982 1
1983 2
1985 1
1986 2
1987 3
1988 2
1989 1
1995 3
1997 2
1998 1
1999 1
2000 1
2002 4
2003 3
2004 1
2005 1
2006 3
2007 2
2008 5
2009 3
2010 3
2011 2
2012 3
2013 4
2014 1
2015 7
2016 9
2017 6
2018 5
2019 9
2020 5
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

98 results
Results by year
Filters applied: . Clear all
Page 1
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye BH, Frank DA, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B, Verma A. Shastri A, et al. Among authors: macleod ar. J Clin Invest. 2018 Dec 3;128(12):5479-5488. doi: 10.1172/JCI120156. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30252677 Free PMC article.
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. Hong D, et al. Among authors: macleod ar. Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272. Sci Transl Med. 2015. PMID: 26582900 Free PMC article. Clinical Trial.
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS. Reilley MJ, et al. Among authors: macleod ar. J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5. J Immunother Cancer. 2018. PMID: 30446007 Free PMC article. Clinical Trial.
Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.
Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, Koechlein CS, Zimdahl B, Yano M, Kopp J, Kritzik M, Sicklick J, Sander M, Grandgenett PM, Hollingsworth MA, Shibata S, Pizzo D, Valasek M, Sasik R, Scadeng M, Okano H, Kim Y, MacLeod AR, Lowy AM, Reya T. Fox RG, et al. Among authors: macleod ar. Nature. 2016 Jun 16;534(7607):407-411. doi: 10.1038/nature17988. Epub 2016 Jun 6. Nature. 2016. PMID: 27281208 Free PMC article.
Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J. Ningarhari M, et al. Among authors: macleod ar. J Hepatol. 2021 May;74(5):1155-1166. doi: 10.1016/j.jhep.2020.11.052. Epub 2020 Dec 15. J Hepatol. 2021. PMID: 33338512 Free article.
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, Pandey SK, Revill M, Rooney C, Buckett LK, Klein SK, Hudson K, Monia BP, Zinda M, Blakey DC, Lyne PD, Macleod AR. Ross SJ, et al. Among authors: macleod ar. Sci Transl Med. 2017 Jun 14;9(394):eaal5253. doi: 10.1126/scitranslmed.aal5253. Sci Transl Med. 2017. PMID: 28615361
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss.
Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL. Arun G, et al. Among authors: macleod ar. Genes Dev. 2016 Jan 1;30(1):34-51. doi: 10.1101/gad.270959.115. Epub 2015 Dec 23. Genes Dev. 2016. PMID: 26701265 Free PMC article.
Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.
Jauvin D, Chrétien J, Pandey SK, Martineau L, Revillod L, Bassez G, Lachon A, MacLeod AR, Gourdon G, Wheeler TM, Thornton CA, Bennett CF, Puymirat J. Jauvin D, et al. Among authors: macleod ar. Mol Ther Nucleic Acids. 2017 Jun 16;7:465-474. doi: 10.1016/j.omtn.2017.05.007. Epub 2017 May 17. Mol Ther Nucleic Acids. 2017. PMID: 28624222 Free PMC article.
98 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page